LeMaitre (LMAT) Reports Earnings Tomorrow: What To Expect
LeMaitre Vascular (NASDAQ: LMAT) will report earnings Tuesday after market close. The prior quarter revenue was $66.55 million, up 11.2% year over year, and it met revenue expectations. For the upcoming quarter, analysts expect revenue growth of 11.5% y/y. The average analyst price target is $118.75 versus $101.32.
How this was made
The 30-second read
Why it matters
Traders can use the provided consensus revenue growth (11.5% YoY) and the company’s recent revenue-estimate miss history to position for earnings volatility, but the text lacks any new guidance or datapoint that would change the fundamental outlook immediately.
Market read
This is an earnings preview with specific consensus and recent performance context, setting expectations for a near-term catalyst rather than introducing new fundamental information.
What to watch
The preview does not quantify margins, guidance details, or order trends; those could dominate the reaction even if revenue growth is only modestly slowing.
Background
LMAT is a medical device company reporting quarterly results Tuesday after market close; the article summarizes last quarter’s revenue beat and the current quarter’s consensus expectations.
Ticker impact
LeMaitre (LMAT) is scheduled to report earnings Tuesday after the close, with revenue and EPS expectations discussed for the print.
Likely elevated volatility into the after-close earnings release, with direction dependent on whether revenue growth re-accelerates and EPS guidance beats.
The article provides concrete consensus expectations (revenue growth 11.5% YoY) and highlights a pattern of missing revenue estimates, but it does not disclose any new company-specific development beyond the upcoming earnings timing.
Market effects
Healthcare equipment peers are referenced as a read-across (Intuitive Surgical down after results, Integra down), which can influence sentiment for the group into LMAT’s print.
No specific regional impact beyond US small/mid-cap healthcare equipment sentiment.
Limited; the read-across is primarily US-listed peers and does not indicate global demand shocks.
Counterpoint
Despite the note that LMAT has missed revenue estimates multiple times, the article also says it beat EPS guidance and reconfirmed estimates, which could support a less negative setup than the miss history implies.
Key entities
- companyLeMaitre Vascular
NASDAQ-listed medical device company scheduled to report earnings Tuesday after the close.
- companyIntuitive Surgical
Peer cited for read-across after its Q2 results, which reportedly led to a 14.1% stock decline.
- companyIntegra LifeSciences
Peer cited for read-across after its Q2 results, which reportedly led to a 13.4% stock decline.
